Barrington Research Lowers Earnings Estimates for Surmodics

Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Research analysts at Barrington Research dropped their Q2 2026 earnings estimates for shares of Surmodics in a research report issued on Thursday, May 1st. Barrington Research analyst M. Petusky now anticipates that the company will post earnings of $0.01 per share for the quarter, down from their prior estimate of $0.03. The consensus estimate for Surmodics' current full-year earnings is $0.20 per share. Barrington Research also issued estimates for Surmodics' Q3 2026 earnings at $0.01 EPS, Q4 2026 earnings at $0.07 EPS and FY2027 earnings at $0.28 EPS.

Other research analysts also recently issued reports about the company. StockNews.com began coverage on Surmodics in a report on Monday, February 3rd. They set a "hold" rating on the stock. Lake Street Capital raised Surmodics from a "hold" rating to a "buy" rating and set a $43.00 price target for the company in a research report on Friday, March 7th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Surmodics in a research report on Wednesday, April 30th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $43.00.

Surmodics Trading Up 0.6 %

NASDAQ:SRDX traded up $0.16 during trading hours on Friday, hitting $27.53. The company had a trading volume of 8,437 shares, compared to its average volume of 276,319. The stock has a 50-day moving average price of $29.13 and a 200 day moving average price of $34.73. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.45 and a quick ratio of 4.29. The company has a market capitalization of $393.65 million, a PE ratio of -27.26 and a beta of 1.32. Surmodics has a 52 week low of $26.00 and a 52 week high of $42.44.

Surmodics (NASDAQ:SRDX - Get Free Report) last posted its earnings results on Wednesday, April 30th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.07). Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%. The company had revenue of $28.09 million for the quarter, compared to analysts' expectations of $32.23 million.

Hedge Funds Weigh In On Surmodics

Several large investors have recently bought and sold shares of the stock. Millennium Management LLC lifted its stake in Surmodics by 0.4% in the 4th quarter. Millennium Management LLC now owns 120,344 shares of the company's stock worth $4,766,000 after acquiring an additional 509 shares in the last quarter. Principal Financial Group Inc. grew its position in Surmodics by 1.8% in the 1st quarter. Principal Financial Group Inc. now owns 36,699 shares of the company's stock worth $1,120,000 after purchasing an additional 638 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of Surmodics by 4.4% during the 4th quarter. Rhumbline Advisers now owns 20,250 shares of the company's stock worth $802,000 after purchasing an additional 861 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of Surmodics by 34.2% in the 4th quarter. Legal & General Group Plc now owns 3,452 shares of the company's stock worth $137,000 after buying an additional 880 shares in the last quarter. Finally, Modus Advisors LLC bought a new stake in Surmodics during the fourth quarter worth about $40,000. Institutional investors and hedge funds own 96.63% of the company's stock.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).